Alnylam Pharmaceuticals
ALNY
$193.67
Share price
2.65%
Change (1 day)
54.32%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) Fails to deliver data
Key failure to deliver metrics for Alnylam Pharmaceuticals :
- Last SEC data release: 2023-05-12
- Last 15 days FTD volume: $0.12 M
- Last 3 months FTD volume: $9.96 M
- Last year FTD volume: $0.13 B
Failures to deliver for Alnylam Pharmaceuticals (ALNY) - 3 month history
Number of shares, 3 month chartBiweekly Failures to deliver volume for Alnylam Pharmaceuticals (ALNY) - since 2013
Volume in USD (price x number of shares), data since 2013Alnylam Pharmaceuticals (ALNY) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2023 | $29.35 M | -81.12% |
| 2022 | $0.15 B | 200.46% |
| 2021 | $51.74 M | -9.83% |
| 2020 | $57.38 M | 52.34% |
| 2019 | $37.66 M | 46.52% |
| 2018 | $25.7 M | -70.97% |
| 2017 | $88.54 M | 191.96% |
| 2016 | $30.32 M | -14.94% |
| 2015 | $35.65 M | 68.07% |
| 2014 | $21.21 M | 152.1% |
| 2013 | $8.41 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Novartis NVS | $29.28 M | $71.27 M | 🇨🇭 Switzerland |
 Sanofi SNY | $7.71 M | $0.11 B | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $14.42 M | $79.47 M | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $5.5 M | $20.45 M | 🇺🇸 USA |
 Regulus Therapeutics RGLS | N/A | $0.29 M | 🇺🇸 USA |
 OPKO Health
OPK | $1.39 M | $13 M | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $19.7 M | $51.29 M | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $1.55 M | $4.89 M | 🇺🇸 USA |